Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 8/20 | 0.35 |
| ▸ | NCF1 | P14598 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 4/20 | 0.34 |
| ▸ | NOS3 | P29474 | 2/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | SHBG | P04278 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21885370 | 0.83 | KDM4E (0.33) | KDM4ECYP3A4MAPTLOXL2HTR7 | |
| SCHEMBL849055 | 0.82 | KDM4E (0.39) | KDM4ECYP3A4MAPTLOXL2HTR7 | |
| SCHEMBL12305653 | 0.82 | SHBG (0.47) | KDM4ECYP3A4MAPTLOXL2HTR7 | |
| SCHEMBL23639185 | 0.82 | ALDH1A1 (0.46) | KDM4ECYP3A4MAPTLOXL2HTR7 | |
| SCHEMBL13339967 | 0.82 | KDM4E (0.52) | KDM4ECYP3A4MAPTLOXL2HTR7 | |
| SCHEMBL16105836 | 0.79 | SHBG (0.46) | KDM4ECYP3A4ESR1ESR2CYP19A1 | |
| SCHEMBL4832407 | 0.78 | KDM4E (0.44) | KDM4ECYP3A4MAPTLOXL2HTR7 | |
| SCHEMBL26802012 | 0.78 | KDM4E (0.44) | KDM4ECYP3A4MAPTLOXL2HTR7 | |
| SCHEMBL1253514 | 0.77 | HTR7 (0.50) | KDM4ECYP3A4MAPTLOXL2HTR7 | |
| SCHEMBL14872331 | 0.77 | SLC6A4 (0.44) | KDM4ECYP3A4MAPTLOXL2HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173628-B2 | Therapy for hormone sensitive diseases; side effect reduction; anticancer agents; osteoporosis; endometriosis; benign prostatic hyperplasia; cardiovascular disorders; acne | NORTHEASTERN UNIVERSITY (US) | 2012-05-08 | — | — | US | disclosed |
| US-8173628-B2 | Therapy for hormone sensitive diseases; side effect reduction; anticancer agents; osteoporosis; endometriosis; benign prostatic hyperplasia; cardiovascular disorders; acne | NORTHEASTERN UNIVERSITY (US) | 2012-05-08 | — | — | US | disclosed |
| US-20080166301-A1 | Steroidal antiestrogens and antiandrogens and uses thereof | NORTHEASTERN UNIVERSITY | 2008-07-10 | — | — | US | disclosed |
| US-20080166301-A1 | Steroidal antiestrogens and antiandrogens and uses thereof | NORTHEASTERN UNIVERSITY | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080166301-A1 | Steroidal antiestrogens and antiandrogens and uses thereof | NR5A1, SHBG, AR | KDM4E 1437/4885CYP3A4 2151/4885MAPT 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.